Kornimate/medical-research-clean huggingface dataset:
study of pg2 injection for improving fatigue in patients after palliative abdominal surgery for cancer

Conditions: Cancer; Surgery; Fatigue

Summary: pg2 has been approved in taiwan to treat cancer-related fatigue for advanced cancer patients. the primary objective of this study is to evaluate the efficacy of pg2 on fatigue relief in patients undergoing palliative abdominal surgery for cancer. the secondary endpoints, including the length of hospital stay, postoperative complications, hrql, inflammatory biomarkers, the duration of antibiotic therapy, mortality during the hospital stay, weight loss and body composition, will be evaluated among these patients.

this will be a double-blind, randomized, and placebo-controlled study. at least 40 evaluable patients who are scheduled for palliative abdominal surgery for cancer will be randomly assigned to the control or treatment group. each group will have at least 20 patients and be treated as follows: 1) control group: patients will accept placebo 1 dose a day (pod-1) before surgery and 1 dose a day for 3 days after surgery (pod+0 to pod+2); 2) treatment group: patients will accept pg2 1 dose a day (pod-1) before surgery and 1 dose a day for 3 days after surgery (pod+0 to pod+2).

Eligibility criteria:
inclusion criteria: * patients who have cancer and are scheduled for palliative abdominal surgery for cancer * age \> 20 years older * patients who signed the informed consent form exclusion criteria: * patients, at screening, has levels greater than 2.5 times the upper limit of normal liver function of alanine aminotransferase or aspartate aminotransferase. * patients has a severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or bun greater than 2.5 times the upper limit of normal for range); or the subject is on dialysis. * patients have ongoing infection, respiratory tract dysfunction, cardiac dysfunction or immune disorder that, in the opinion of the investigator, may interfere with conduct of the study. * patients who are not suitable for undergoing surgery (e.g. congenital hemostatic disorders) by the investigator's judgment. * patients have enrolled or have not yet completed other investigational drug trials within 1 month before screening. * female patients are pregnant or breast-feeding. * patients who require preoperative nutritional support * patients with serious comorbidities (american society of anesthesiologists risk class of 4 or 5). * patients who is unwilling or unable to answer the quality of life questionnaires i.e. the bfi-t and eortc qlq-c30.

Keywords: cancer-related fatigue palliative abdominal surgery hrql
developing fast pediatric imaging

Conditions: Pediatric Low-grade Gliomas

Summary: this research study is evaluating the investigational software for magnetic resonance imaging (mri) systems and techniques to process magnetic resonance (mr) images

the purpose of the study is to develop new technologies for mri systems. the new technologies should improve mri capabilities in terms of how sensitive, specific, and efficient they are. the overall goal is to get better measurements of the brain tumor tissue(s). in this research study, the investigators want to learn more about investigational software and about techniques to process mr images. the testing of investigational software will allow the investigators to improve the image quality. as part of the testing process, the investigators will collect more mr images of the brain, and improve current image reconstruction methods. this will allow a more precise analysis of mr images and potentially better assessment of the brain tumor tissue volume.

Eligibility criteria:
inclusion criteria: * infants, children and adults who have been diagnosed with low grade glioma * healthy volunteers - children from age 0 to adults with no upper age limit or; * diagnosed with lgg and being treated at dfci; exclusion criteria: * electrical implants such as cardiac pacemakers or perfusion pumps; * ferromagnetic implants such as aneurysm clips, surgical clips, prosthesis, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants; * ferromagnetic objects such as jewelry or metal clips; * women of childbearing age who are seeking to become pregnant, who are breastfeeding, or who suspect they may be pregnant; * pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions; * any greater than normal potential for cardiac arrest

Keywords: neuro oncology
a study of daily oral orforglipron (ly3502970) compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk

Conditions: Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney Disease

Summary: the main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. the study will last approximately 2 years may include up to 27 visits.


Eligibility criteria:
inclusion criteria: * have been diagnosed with type 2 diabetes mellitus (t2dm) * are at least 18 years of age or legal age of consent in the jurisdiction in which the study is taking place, whichever is older. * have hba1c at screening * ≥7.0% and ≤10.5% if background diabetes medication does not include a sulfonylurea, or * ≥7.5% and ≤10.5% if background diabetes medication includes a sulfonylurea. * are on stable treatment of at least 1 and no more than 3 oral antihyperglycemic drugs for at least 90 days before screening. antihyperglycemic drugs may include metformin, sglt-2 inhibitors, and/or sulfonylureas * have increased risk for cardiovascular (cv) events due to: * coronary heart disease * peripheral arterial disease, presumed to be of atherosclerotic origin * cerebrovascular disease, presumed to be of atherosclerotic origin * chronic kidney disease (ckd) * congestive heart failure (chf) new york heart association (nyha) functional classification ii to iii * are of stable weight (± 5%) for at least 90 days prior to screening * have a bmi ≥25 kilograms per meter squared (kg/m2) at screening exclusion criteria: * have type 1 diabetes mellitus * have had chronic or acute pancreatitis any time prior to screening * currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (e.g. laster photocoagulation or intravitreal injections of anty-vegf inhibitors * have a known clinically significant gastric emptying abnormality * have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (alt) or aspartate aminotransferase (ast) enzyme level ≥5.0 times the upper limit of normal (uln) for the reference range, as determined by the central laboratory * have had any of the following within 60 days prior to screening: acute myocardial infarction, cerebrovascular accident (stroke), or hospitalization for congestive heart failure * have an egfr \<15 ml/min/1.73 m2 as determined at screening * have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 * have been taking any other diabetes medicines other than metformin, sglt-2 inhibitors, and/or sulfonylureas during the last 90 days * have used any weight loss drugs, including herbal or nutritional supplements, within 90 days of screening
a study of danicopan in participants with geographic atrophy secondary to age-related macular degeneration

Conditions: Geographic Atrophy

Summary: this is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with ga secondary to amd. the study consists of a screening period of up to 6 weeks, a 104-week masked treatment period, followed by a 30-day follow-up after the last dose. this study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.


Eligibility criteria:
key inclusion criteria: * vaccination for neisseria meningitidis. * capable of giving signed informed consent. * presentation of ga secondary to amd in at least 1 eye * the entire ga lesion must be \> 1 μm outside of the foveal center key exclusion criteria: * ga in the study eye due to cause other than amd. * have previously received intravitreal anti-vascular endothelial growth factor injections in study eye for intraocular vascular disease. * have previously received any stem cell/gene therapy for any ophthalmological condition in either eye. * use of any investigational medicinal product (ie, participation in interventional clinical studies for any ophthalmic indications) or use of any regulatory approved treatment for ga in the study eye regardless of route of administration within the last 3 months or 5 half-lives of the last dose of the investigational or commercial product (whichever is longer). * presence of active ocular diseases in the study eye that in the opinion of the investigator compromises or confounds visual function or interferes with study assessments. * known or suspected complement deficiency. * history or presence of any medical or psychological condition that, in the opinion of the principal investigator, would make the patient inappropriate for the study. * hypersensitivity to fluorescein sodium for injection, the investigational drug (danicopan) or any of its excipients. note: additional inclusion/exclusion criteria may apply, per protocol.

Keywords: geographic atrophy ga danicopan alxn2040 complement inhibition amd
c11 amt positron emission tomography (pet) imaging in patients with metastatic invasive breast cancer

Conditions: Breast Cancer

Summary: the purpose of this research project is to create images of where and how the amino acid (the building blocks of proteins)tryptophan is processed in normal and abnormal tissue in the patient's body. tryptophan is a normal building block of proteins in the body. sometimes in the case of cancer and other diseases, tryptophan is processed abnormally, and possible treatments for this abnormality are of great interest because of the potential to improve cancer care.

coordinating center: southeast phase 2 consortium (sep2c), moffitt cancer center. research participation involves up to three experimental imaging examination visits in radiology: a baseline before the patient starts a cancer treatment, a follow-up a few days later, and a later follow up to see how the treatment may affect normal or abnormal processing of tryptophan. the research imaging results will be linked with other evidence of the patient's disease, but will not effect their care.

Eligibility criteria:
inclusion criteria: * patients must be enrolled on the nci 8461/mcc 16025 study. * consent for participation in this companion imaging study and be able to successfully complete a minimum of two amt pet/ct scans. exclusion criteria: * patients must not meet any of the exclusion criteria for the nci 8461/ mcc 16025 study. * not have any medical conditions prohibiting the successful completion of a minimum of two amt pet/ct scans.

Keywords: breast - male breast - female metastatic invasive
application and benefit evaluation of wearable technology and information software-based psychological stress monitoring in return-to-work healthcare for injured workers: a longitudinal study

Conditions: Injury; Return to Work; Mental Health

Summary: objective this study aims to develop and evaluate a multidisciplinary service model that integrates wearable devices and mobile health applications to monitor the physical and mental health of workers with occupational injuries during their return-to-work process. background with advances in digital health, smartwatches and mobile applications are increasingly used in healthcare to support personalized monitoring and intervention. this project targets injured workers attending occupational medicine clinics, using smartwatches to monitor physiological data and a mobile application to assess psychological status. the model includes remote mental health support and aims to assess its impact on return-to-work outcomes and psychological well-being. methods a total of 120 eligible injured workers will be randomly assigned to an intervention or control group. all participants will receive standard outpatient care. the intervention group will additionally use a smartwatch for physiological monitoring and a mobile app for daily to weekly psychological assessments. the 6-month follow-up will evaluate return-to-work success rate, time to return, post-return quality of life, and mental health status. intervention tools the ntu medical genie, labfront, and line@ platforms will facilitate real-time monitoring and batch downloading of smartwatch data, as well as the distribution of mood and stress-related questionnaires. at least three occupational rehabilitation education modules will be developed, and case managers will deliver individualized health education and psychological support. expected outcomes the study will assess the effectiveness of this technology-supported, cross-disciplinary care model in improving return-to-work outcomes, mental health, and quality of life. it will also explore participant satisfaction and acceptance of the model. the findings are expected to inform future occupational health interventions and enhance care quality for injured workers.


Eligibility criteria:
inclusion criteria: * (1) injured workers aged 18 to 65 years. * (2) currently receiving follow-up care at the occupational medicine outpatient clinic of this hospital. * (3) expressed willingness to return to work. * (4) ability to access the internet and operate the mobile application using a smartphone. exclusion criteria: * (1) individuals not expected to regain work capacity of at least 3 hours per day within six months. * (2) individuals who have resigned and do not intend to return to work within six months.
opioid counseling following orthopaedic surgery

Conditions: Orthopedic Disorder

Summary: postoperative pain management and opioid consumption following outpatient orthopaedic surgery may be influenced by a number of variables including knowledge of safe opioid use. a prospective randomized study is designed to understand the effect of preoperative opioid counseling on postoperative opioid consumption and the typical opioid consumption patterns following common outpatient orthopaedic surgeries. the hypothesis was that patients who received preoperative opioid counseling will consume less postoperative opioid medication and experience greater satisfaction with pain management.


Eligibility criteria:
inclusion criteria: * patients undergoing shoulder, elbow, wrist, knee, foot, and/or ankle surgery exclusion criteria: * male of female less than 18 years old * patients schedule to undergo inpatient procedures * patients undergoing surgeries distal to the wrist * patients undergoing surgeries under local anesthesia only
depression in chronic airways diseases

Conditions: Chronic Lung Disease

Summary: chronic airways diseases involve alterations in the person's social roles, relationships and self-perception so demands continual psychological adjustment . also kunik studied patients with chronic breathing disorders for depression and anxiety and found that 65% of patients were positive for depression and anxiety. shackell found that patients' anxiety and fears of breathlessness and dying extended into the night and were aggravated by feelings of isolation and frustration. one patient reported that they often thought 'am i going to see the next morning?'

this fear and sense of helplessness can lead to panic and evidence suggests that patients with chronic breathlessness often call for emergency assistance during the night according to gold report 2017, anxiety and depression in chronic obstructive pulmonary disease patients are both associated with poor prognosis. much of the evidence explored so far relates to chronic obstructive pulmonary disease. while other chronic lung diseases have received less attention in addition to, several studies have been found relationship between asthma and psychological disturbance .one review of literature describes an increased prevalence of psychological co-morbidity in asthmatic adults and another research suggests that anxiety and depression are more common in patients with moderate to severe asthma than in the general population gift. found significantly greater self-reported depression scores among patients with chronic obstructive pulmonary disease receiving prednisone compared to patients not receiving any steroids. interestingly, the psychiatric sequel of steroid treatment are often sudden in onset and appear to generally occur within 2 weeks after steroid introduction

Eligibility criteria:
inclusion criteria: * chronic airways diseases as chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis exclusion criteria: * diabetes mellitus and hypertension. * cardiac diseases. * chronic renal and liver diseases.
the effects of arixtra on wound drainage following total joint arthroplasty

Conditions: Total Knee Replacement

Summary: the investigators hypothesize that arixtra patients will be less likely to experience wound infection than patients who have received low-molecular weight heparin, coumadin or aspirin with mechanical compression.


Eligibility criteria:
inclusion criteria: * all primary unilateral tka and tha cases will be included. exclusion criteria: * patients less than 50 kg, patients with crcl\<30ml/min. revision and bilateral procedures will be excluded.
a trial of azithromycin sr for the treatment of acute bronchitis and secondary infection of chronic respiratory diseases

Conditions: Acute Bronchitis

Summary: to evaluate the clinical efficacy and safety in patients with acute bronchitis or secondary infection of chronic respiratory diseases receiving a dose of 2 g of azithromycin in the sr formulation.


Eligibility criteria:
inclusion criteria: * patients who were diagnosed as mild or moderate in severity by the classification of infection of the japanese society of chemotherapy guidelines for the evaluation methods of new antibacterial drug (established in 1997). exclusion criteria: * severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.
caffeine and cataract after pars plana vitrectomy

Conditions: Cataract

Summary: assessment of cataract development in patients with regular caffeine consumption and those without caffeine consumption after pars plana vitrectomy.

vitrectomy is a frequently used surgical procedure in ophthalmology for various indications like retinal detachment repair or macular pucker peeling. amongst others, accelerated cataract development in phakic patients is a known complication after vitrectomy. a previous study found that especially patients receiving gas tamponade are at increased risk for postoperative cataract development. the assumed mechanism behind this finding is that vitrectomy leads to an increased partial pressure of o2 in the human vitreous - similar to that observed in posterior vitreous detachment - subsequently leading to accelerated lens opacification. therefore, a possible target of cataract prevention is the inhibition of oxygen radical formation. one known antioxidant agent inhibiting oxygen radical formation is caffeine. for instance, in-vitro studies showed that caffeine consumption can reduce cataract development in ultraviolet (uv)-radiation-exposed rats and human lens epithelial cells through its capability of inhibiting oxygen radical formation. these in-vitro studies support the findings of epidemiological studies that caffeine also in-vivo has the potential to reduce cataractogenesis. conflating the previous findings of accelerated cataract formation after vitrectomy and the preventive properties of caffeine for cataract development, there may be a benefit for patients regularly consuming caffeine-containing beverages like coffee undergoing vitrectomy regarding postoperative cataract formation. therefore, the aim of this comparative study is to investigate if patients undergoing small gauge pars plana vitrectomy regularly consuming caffeine have lower postoperative significant cataract formation rates than patients not consuming caffeine.

Eligibility criteria:
inclusion criteria: * age 18 or older * written informed consent * no previous cataract surgery in the study eye * scheduled small gauge vitrectomy with intraoperative gas tamponade (sf6 or c3f8) due to retinal detachment or macular hole repair * no regular caffeine consumption (drinking not more than one cup of a caffeine- containing beverage \[e.g. coffee, energy drinks\] at a maximum of two days per week during the past year) exclusion criteria: * intake of systemic or topical corticosteroids within 3 months before study screening * increased risk for postoperative cataract development, for example due to ocular trauma in the history * severe cataract (locs iii grading of any cataract form \>2) in the study eye at pre- study screening * scheduled phacovitrectomy in the study eye * participation in any clinical trial three month before study screening * ocular surgeries six month before study screening

Keywords: pars plana vitrectomy caffeine retinal detachment macular pucker
does autologous conditioned plasma enhance rotator cuff tendon healing after surgery?

Conditions: Supraspinatus Tear

Summary: the aim of this study is to establish if the application of autologous conditioned plasma (acp), also described as platelet rich plasma (prp), to the site of supraspinatus tendon repair beginning within two weeks of surgery, can improve patient outcomes over the course of 12 months. these outcomes will be measured by post-surgical pain and function scores, shoulder strength and range of motion (rom), and radiological parameters of tendon healing. outcome measures will be compared to a control group of patients receiving placebo injections following surgery (saline plus local anaesthetic). this study is significant for being the first double blind randomised control trial, using two prp injections to examine the efficacy of a prp preparation following surgical repair of supraspinatus tendon. the objective is to prolong and enhance the tendon healing response initiated by surgery. the research hypothesis is that enhanced tendon healing following the prp injections will lead to more rapid rehabilitation and lower rates of re-rupture of the repaired tendon compared to the control group.


Eligibility criteria:
inclusion criteria: * aged 50-75 years; * in a non-dependent relationship; * full-thickness supraspinatus tendon tear (deemed repairable); * pre-operative platelet count greater than 150 000. exclusion criteria: * previous rotator cuff repair surgery; * active/distal infection; * metabolic bone or blood disorders; * pre-existing conditions associated with upper extremity pain; * rotator cuff tears secondary to fracture; * prior acp/prp injections; * non-surgical rotator cuff treatment in the past month, including corticosteroids and anti-inflammatory treatment.

Keywords: rotator cuff tendon repair surgery supraspinatus tendon repair